PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of nihpaAbout Author manuscriptsSubmit a manuscriptHHS Public Access; Author Manuscript; Accepted for publication in peer reviewed journal;
 
Structure. Author manuscript; available in PMC 2010 April 22.
Published in final edited form as:
PMCID: PMC2858361
NIHMSID: NIHMS187055

The Human Breast Cancer Resistance Protein (BCRP/ABCG2) Shows Conformational Changes with Mitoxantrone

Summary

BCRP/ABCG2 mediates efflux of drugs and xenobiotics. BCRP was expressed in Pichia pastoris, purified to > 90% homogeneity, and subjected to two-dimensional (2-D) crystallization. The 2-D crystals showed a p121 symmetry and projection maps were determined at 5-Å resolution by electron cryomicroscopy. Two crystal forms with and without mitoxantrone were observed with unit cell dimensions of a = 55.4 Å, b = 81.4 Å, γ = 89.8°, and a = 57.3 Å, b =88.0 Å, γ = 89.7°, respectively. The projection map without mitoxantrone revealed an asymmetric structure with ring-shaped density features probably corresponding to a bundle of transmembrane α-helices, and appeared more open and less symmetric than the map with mitroxantrone. The open and closed inward-facing forms of BCRP were generated by homology modeling, representing the substrate-free and substrate-bound conformations in the absence of nucleotide, respectively. These models are consistent with the experimentally observed conformational change upon substrate binding.

Introduction

Resistance to anticancer agents is a major cause of chemotherapeutic failure in cancer. One mechanism involves active extrusion of drugs out of cells by membrane transport proteins resulting in cellular drug levels below that required for cytotoxicity. Clinical and in vitro cell-based studies have shown that multidrug resistance is often associated with increased expression of one or more transport proteins belonging to the ATP-binding cassette (ABC) transporter superfamily which use the energy provided by ATP binding and hydrolysis at their nucleotide binding domains (NBDs) to transport substrates across the cell membrane (Sarkadi et al., 2006). The most important eukaryotic ABC transporters involved in multidrug resistance are P-glycoprotein (P-gp/ABCB1), multidrug resistance protein 1 (MRP1/ABCC1) and breast cancer resistance protein (BCRP/ABCG2).

The 75 kDa human BCRP is a polytopic plasma membrane transport protein which has been detected in many drug-resistant cell lines, solid tumors, and hematological malignancies (Robey et al., 2009). Transport studies using BCRP-overexpressing intact cells or BCRP-enriched plasma membrane vesicles have established that BCRP can actively transport a broad spectrum of substrates, ranging from hydrophobic chemotherapeutics to hydrophilic anionic conjugated endo- and xenobiotics (Mao and Unadkat, 2005; Polgar et al., 2008). BCRP is highly expressed in organs important for the absorption (the small intestine), distribution (e.g., the blood-brain and placental barriers), and elimination (e.g., the liver and kidney) of drugs (Maliepaard et al., 2001), and plays an important role in drug disposition (Mao and Unadkat, 2005; Robey et al., 2009).

ABC transporters usually consist of two hydrophobic transmembrane domains (TMDs) with 12 transmembrane (TM) α-helices and two hydrophilic NBDs for substrate and ATP binding, respectively (Sarkadi et al., 2006). P-gp and MRP1 are arranged in two repeated halves with 12 and 17 TM α-helices, respectively, forming a funnel facing the outside of cell membrane (Loo and Clarke, 2001; Rosenberg et al., 2005) and a higher resolution structure of P-gp was recently described (Aller et al., 2009). In contrast, BCRP is a half ABC transporter with one NBD followed by one TMD (Polgar et al., 2008). The most recent topology analysis suggests that the TMD of BCRP consists of 6 TM α-helices (Wang et al., 2008). Hence, BCRP appears to require homodimerization to exert its activity and a homotetrameric configuration of BCRP has been proposed (McDevitt et al., 2006; Xu et al., 2004). The substrate specificity of BCRP is overlapping with, but distinct from that of P-gp and MRP1 (Mao and Unadkat, 2005; Polgar et al., 2008). TM6 and TM12 of P-gp are involved in drug binding (Loo and Clarke, 2001). It has been shown that arginine at position 482 of BCRP which is located within TM3 near the cytosolic membrane interface is critical for substrate specificity and transport activity, suggesting that an alternative drug binding mechanism is applicable for BCRP (Honjo et al., 2001; Ozvegy-Laczka et al., 2005).

Structural features responsible for such differences in drug binding and transport mechanisms of different ABC transporters are yet not known. Indeed, little is known about the structure of BCRP, although an atomic model of BCRP was recently predicted by homology modeling based on the crystal structure of the bacterial multidrug exporter Sav1866, which suggested that BCRP had multiple drug binding sites (Hazai and Bikadi, 2008). We have previously reported functional expression of human BCRP at a relatively high level in Pichia pastoris (Mao et al., 2004). BCRP expressed in Pichia pastoris was active in transporting its substrate estrone 3-sulfate and in hydrolyzing ATP. This suggested that Pichia pastoris could be used to overexpress and purify BCRP for structural analysis. In this study, we have purified BCRP from Pichia pastoris, facilitated by a 10-histidine tag attached to the COOH-terminus of the transporter. Electron crystallography has emerged as a powerful tool to determine the structures of membrane proteins from 2-D crystals, including that of P-gp (Rosenberg et al., 2005) and several at atomic resolutions (Gonen et al., 2005; Holm et al., 2006; Kuhlbrandt et al., 1994). We have captured structural information of BCRP from 2-D crystals which were grown in the presence and absence of the substrate drug mitoxantrone, analyzed by electron cryomicroscopy, and projection structures determined at 5-Å resolution. Conformational changes were observed in 2-D crystals grown in the absence and presence of mitoxantrone. Analysis and homology modeling of the differences between these structural states also indicated a significant conformational change. This structural information provides a basis for further structural and mechanistic analysis of BCRP and related ABC proteins.

Results and Discussion

Production and characterization of BCRP expressed in Pichia pastoris

Recombinant full-length human BCRP with a 10-histidine tag attached at the COOH-terminus of the protein was expressed in Pichia pastoris as previously described (Mao et al., 2004). The expression of BCRP in Pichia pastoris was detected by immunoblotting of the microsomes with the monoclonal antibody BXP-21 and a major immunoreactive band of approximately 65 kDa was observed (Figure 1A). Solubilization of BCRP from crude microsome membranes was evaluated using several detergents. Approximately 50% of BCRP was solubilized by lysophosphatidylcholine (LPC) at a LPC/protein ratio (mg/mg) of more than 5. N-dodecyl β-D maltoside (DDM) was more effective than LPC which solubilized more than 90% of BCRP at a relatively low DDM/protein ratio (mg/mg) of 2 at 4°C.

Figure 1
Expression, purification, and ATPase activity of BCRP

The detergent extract of BCRP was subjected to Ni2+-NTA affinity chromatography. Comparison of the detergent-extract and flow through suggested that more than 70% of the DDM-solubilized BCRP bound to Ni2+-NTA as visualized on silver stained SDS-PAGE (Figure 1B, lanes 1 – 3). BCRP was purified to more than 90% homogeneity visualized as an approximately 65-kDa full-length underglycosylated protein with no apparent contaminating bands (Figure 1B, lanes 4 – 8). An immunoblot confirmed that these bands were BCRP (data not shown). Further purification by anion exchange chromatography was precluded because the protein was thought to be sufficiently pure. The overall yield of BCRP purified from 1.0 L of yeast culture was approximately 200 μg. This BCRP preparation was suitable for electron crystallography by growing the crystals directly on the surface of an electron microscope (EM) grid, which requires less protein (Rosenberg et al., 2005).

Purified BCRP in detergent solution was active in hydrolyzing ATP with a basal activity of approximately 20 – 60 nmol Pi/min/mg protein (Figure 1C and 1D), which could be modulated by prazosin (Figure 1E), a known BCRP substrate that has been shown to stimulate BCRP ATPase activity (Glavinas et al., 2007). This finding suggests that the purified BCRP remains correctly folded in a non-reconstituted environment and the protein had retained its activity through the purification process. The relatively low basal ATPase activity of BCRP was likely due to BCRP presenting in a non-reconstituted membrane environment, but was in a similar range of the ATPase activity of BCRP purified from insect cells (Pozza et al., 2006).

Two-dimensional crystals of BCRP in different conformational states

Well-ordered 2-D crystals of BCRP were grown in the presence of DDM as previously described (Rosenberg et al., 2005), except that the crystals here were grown directly on the surface of continuous carbon/molybdenum or carbon/gold grids at 4°C. In general, the crystals were larger and better ordered than the P-gp crystals and thus more suitable for structure analysis by electron crystallography (Figure 2). These crystals were sometimes 1.5 micrometer in width and 1.5 micrometer in length, and appeared visually different to those of P-gp (Rosenberg et al., 2003) and CFTR (Rosenberg et al., 2004), having less of a “honeycomb” and a more of “square shaped” appearance suggesting a different space group compared with P-gp and CFTR (see below). The crystals were grown in the presence or absence of 5 mM mitoxantrone by adding this drug to the appropriate crystallization droplet.

Figure 2
Negatively stained 2-D crystals of BCRP of the p121 type stained with 2% (w/v) uranyl acetate

The crystals were initially negatively stained, but to extend the resolution of the data, electron cryomicroscopy was undertaken (Rosenberg et al., 2005). Two different types of crystal forms were observed. The calibrated unit cell parameters for the monoclinic type crystal form in the absence of mitoxantrone were a = 57.3 ± 0.7 Å (n = 5), b = 88.0 ± 0.95 Å (n = 5), γ = 89.7 ± 0.6 ° (n = 5), whilst the other crystal form in the presence of mitoxantrone measured a = 55.4 ± 0.6 Å (n = 5), b = 81.4 ± 1.1 Å (n = 5), γ = 89.8 ± 0.5 ° (n = 5) (Table I). In general, the crystals in the presence of the drug were larger and better ordered than the crystals in the absence of the drug. This significant change in unit cell dimensions, especially in the b direction, suggests that the crystal packing has changed in the presence of mitoxantrone and BCRP has adopted different conformations. Recent studies for NhaA, the Na+/H+ exchanger from E. coli, also demonstrated changes in unit cell dimensions concomitant with conformational changes and showed that one crystal form was better ordered than the other (Appel et al., 2009). The 2-D crystals of BCRP had a two-sided plane group p121 symmetry determined by ALLSPACE (Valpuesta et al., 1994). Gamma (γ) could have been very slightly less than the required 90 degree angle for this space group because of a slight crystal tilt on the electron microscope grid for both mitoxantrone and non-mitoxantrone crystal forms (Valpuesta et al 1994). This space group is different to that for P-gp and CFTR.

Table I
Crystallographic image processing data for 2-D crystals of BCRP

Low-dose images of frozen-hydrated crystals preserved in ice showed strong reflections at ~ 8 Å by optical diffraction. After correction for lattice distortions, the crystals in the presence of mitoxantrone yielded structure factors to 4.0 Å resolution (Figure 3A). In the absence of mitoxantrone, the crystals were slightly less well ordered; however, the corresponding deviation map (Figure 1S) of the 2-D crystals with vectors (magnified 20×) between the perfect adapted lattice and the actual unit cell positions suggests that the drug-free crystals are also well ordered, especially in the center of the crystals. A plot of the phase quality shows that these crystals extend to 8 Å resolution (data not shown). For these crystals the Mathews coefficient calculated with CCP4 (Bailey, 1994) suggested that there were 4 BCRP monomers (two BCRP dimers) in the asymmetric unit cell assuming that the molecular mass of each BCRP monomer was 65 kDa. McDevitt et al. (McDevitt et al., 2006) reported a tetrameric 3-D structure for BCRP purified from insect cells in which different detergents were used for extraction and purification of BCRP. It has been documented that the association state of membrane proteins can depend on the detergent used (Larue et al., 2009). However, both the projection maps of this study and the previously reported 3-D map could be consistent with a tetrameric structure because the tetramer would consist of four homodimeric BCRP molecules.

Figure 3
Diffraction patterns of the BCRP crystals

Projection maps of 2-D crystals of BCRP in the presence and absence of mitoxantrone with data truncated at 5-Å resolution and a p121 symmetry enforced were calculated after merging data from six and five independent lattices, respectively (Figure 4). The overall average phase residual was 35 ° and 25 ° for the drug-free and drug-bound crystal forms, respectively (Table I). A single crystal image exhibited a screw axis, providing confidence in the assignment of the space group and the value of the Mathews coefficient. In both crystal forms, the unit cell contains two BCRP homodimers related by a 2-fold screw axis along b with the dimer being present in alternately up and down orientations. Each homodimer is composed of two polypeptide chains related by a non-crystallographic 2-fold axis of rotational symmetry. The BCRP molecules were clearly delineated, but the packing of the dimers is different in the two crystal forms. The BCRP dimers in the presence of mitoxantrone were rotated ~20° relative to the no drug crystal form, resulting in a closer inter-dimer packing (Figure 4B). The introduction of additional close contacts between the BCRP dimers presumably resulted in a better crystalline order in the presence of the drug. Consequently, the shape of the BCRP molecules was different between the two maps with the BCRP molecules having a more closed configuration in the presence of mitoxantrone (Figure 4B) and a more open shape in the absence of the drug (Figure 4A). A difference map between the drug-free and drug-bound forms was calculated (Figure 2S). The main changes appear to be a small solid body rotation around the crystal normal and, as implied by the unit cell parameters, a compression of the structure in the presence of mitoxantrone. These data suggest that, in the presence of mitoxantrone, BCRP has undergone a significant conformational change. This seems to fit with the interpretation in the models of a drug-induced closing up of the transporter, which has implications for the mechanisms of ABC transporters in general (see below).

Figure 4
Projection maps of 2-D crystals of BCRP at 5 Å resolution

For X-ray structures of the bacterial ABC lipid transporter, MsbA, trapped in different conformations, two nucleotide-bound structures and two in the absence of nucleotide, were recently reported (Ward et al., 2007). The two nucleotide-bound structures share the same outward-facing conformation, whereas the two nucleotide-free apo structures have different inward-facing conformations. The TMDs of MsbA are much closer in the closed apo conformation than in the open apo conformation. These authors suggested that the closed apo conformation might represent an intermediate conformation between the open apo and the nucleotide-bound outward-facing conformations, and that substrate binding to the open apo conformation may promote the closure of the TMDs of MsbA, which would, in turn, send a signal to the NBDs, allowing the formation of the ATP sandwich upon nucleotide binding. The finding of this study that the projection maps of BCRP display a more closed conformation in the presence of mitoxantrone and a more open shape in the absence of the drug appears to be consistent with the structural data of MsbA.

Each BCRP monomer is predicted to contain 6 TM α-helices (Wang et al., 2008). In EM images obtained under cryoconditions, the entire protein contributes to the information contained in the images; thus, the extramembranous features as well as the TM elements may be superimposed in EM projection maps. Long α-helices with axes close to the crystal normal could give rise to strong 0.8–1 nm diameter features in the projection map. At approximately 5-Å resolution, the spacing and dimensions of some of the typical strong densities in the BCRP projection maps maybe consistent with those of TM α-helices (Figure 4). The resolution of the projection maps is not sufficient to interpret any of the densities as arising from reentrant loops such as those observed in aquaporin (Murata et al., 2000) or those suggested to be present in bacterial transporters, neurotransmitter transporters, and ion exchanger antiporters (Slotboom et al., 1999; Wakabayashi et al., 2000).

Membrane topology of BCRP

Although a high resolution 3-dimensional structure of BCRP has not been available, homology models of BCRP have been reported (Hazai and Bikadi, 2008; Li et al., 2007). To further understand the interactions between BCRP monomers in the 2-D crystals, it would be of value to fit homology models of BCRP to the projection maps we have obtained. However, the currently available homology models do not appear to correctly predict the real structure of BCRP as these models were based on the computer prediction of BCRP topology structure, which is quite different from the experimentally determined topology structure (see below). Moreover, the currently available homology models represent a substrate-free and nucleotide-bound conformation of BCRP, which seems unsuitable to interpret the projection structures of this study obtained with and without a substrate in the absence of nucleotide. Therefore, we first performed relevant homology modeling based on the topology structure of BCRP we recently determined (Wang et al., 2008). A major difference between the experimentally determined topology structure and computer prediction is that the computed-predicted TM2 and TM5 are shifted to the extracellular and intracellular loops in the experimental model, respectively (Wang et al., 2008). To further confirm this significant shift, we generated additional HA-tagged BCRP mutants using HA tag insertion mutagenesis, one at a time, at positions immediately following the residues 435 (construct 435-HA), 445 (construct 445-HA), 460 (construct 460-HA), 470 (construct 470-HA), 540 (construct 540-HA), and 550 (construct 550-HA). Wild-type and HA-tagged mutant BCRP were expressed in HEK cells by transit transfection. Immunoblotting using the BXP-21 antibody detected wild-type BCRP and all the mutants at comparable levels (Figure 5A). When immunoblotting was performed using a monoclonal antibody against the HA tag, immunoreactive bands of approximately 75 kDa were observed for all the mutants, but were absent for the vector control or wild-type BCRP (Figure 5A). These results suggest that all the HA-tagged BCRP mutants were well expressed in HEK cells at levels comparable to wild-type BCRP. Immunofluorescence analysis was then performed with intact cells or cells that had been permeabilized with Triton X-100 to determine extracellular or intracellular location of the HA tags, respectively. No cell-based fluorescence was detected in intact or permeabilized nontransfected control cells (data not shown) or in cells expressing wild-type BCRP (Figure 5B). However, a strong immunofluorescence signal was detected in both intact and permeabilized cells expressing the mutants with HA tag insertions at residues 435 (construct 435-HA, Figure 5B, b and e) and 445 (construct 445-HA, Figure 5B, c and f), suggesting the extracellular location of the HA tags at positions 435 and 445. In contrast, cells expressing the mutants with HA tag insertion at residues 540 (construct 540-HA, Figure 5B, i and m) and 550 (construct 550-HA, Figure 5B, j and n) showed bright fluorescence only in permeabilized cells, but not in intact, nonpermeabilized cells. This demonstrates the intracellular location of the HA tags at positions 540 and 550. The fluorescence signal associated with the mutants with HA tag insertion at residues 460 (construct 460-HA, Figure 5B, g) and 470 (construct 470-HA, Figure 5B, h) was rather weak, and could be barely detected only in permeabilized cells, suggesting that the HA tag at these positions is located in a region with limited accessibility to the antibody. Thus, the residues 460 and 470 are likely located in a TM segment. For all the mutants, fluorescence staining was mainly observed in the plasma membrane (Figure 5B), suggesting that these mutants were predominantly targeted to the plasma membrane of HEK cells. These immunoblotting and confocal microscope data indicate that HA tag insertion in all of the mutants does not appear to cause a major alteration in BCRP structure that can affect protein stability, expression, folding, and targeting to the plasma membrane. The mitoxantrone efflux activity of the mutants were approximately 11.7%, 3.6%, 4.2%, 15.3%, 9.7%, and 34.0% of wild-type BCRP activity for constructs 435-HA, 445-HA, 460-HA, 470-HA, 540-HA, and 550-HA, respectively (data not shown). The activity data indicate that, except for constructs 445 and 460, other mutants retained at least partial transport activity, confirming that sufficient amounts of these mutants were correctly folded and targeted to the plasma membrane to exert efflux activity. The decreased activities may reflect functional importance of the positions at which the tag is inserted, rather than major structural alterations. Taken together, these data further support the topology structure of BCRP we previously reported (Wang et al., 2008). As shown in Figure 5C, the residues 431 – 450 which were predicted to be part of TM2 were now found to be in an extracellular region, whereas residues 460, 462, and 470 that were predicted in an intracellular loop were determined to be in the TM2. The residues 562 – 582 predicted to be in an extracellular loop were determined to form the TM5. The computer-predicted TM1, TM3, TM4, and TM6 are in correspondence with the experimental data.

Figure 5
Analysis of membrane topology of BCRP by HA tag insertion and immunofluorescence confocal microscopy as well as the topology model of BCRP

Homology modeling of BCRP

Our earlier BCRP model (Hazai and Bikadi, 2008) was constructed using the Sav1866 structure (Dawson and Locher, 2006) as template and reflects the nucleotide-bound outward-facing conformation. Owing to the low amino acid identity particularly in the TMDs among ABC transporters, the membrane topology of BCRP used in our previous study was primarily based on computer predictions. However, our experimental data clearly indicate that there are crucial differences between the predicted and the experimentally determined topology structures. Except for two regions, the overall topology structure of BCRP deduced from the experimental data is surprisingly similar to that of P-gp observed in its X-ray structure (Aller et al., 2009) (Figure 5C). First, the relatively large intracellular loop connecting TM2 and TM3 that contains a coupling helix to interact with the NBD of the same monomer as seen in the X-ray structures of P-gp, Sav1866, and MsbA is missing in BCRP. As a result, TM3 of BCRP is rather short and does not intrude into the intracellular loop. Second, the extracellular loop connecting TM5 and TM6 of BCRP is significantly longer than the corresponding region in P-gp. Figure 3S shows a multiple sequence alignment between the templates used for homology modeling and BCRP based on the experimentally determined topology. The order of TMD and NBD of the templates was switched to reflect that of BCRP and the linker region was deleted. The resulting sequence alignment suggests that the number of gaps is considerably lower and the amino acid identity in the TMD is much greater than that of sequence alignments solely based on TM computer predictions (Hazai and Bikadi, 2008; Li et al., 2007). The overall amino acid identity between the TMDs of BCRP and the first half of mouse P-gp is approximately 18% without gaps. Furthermore, most of the putative TM α-helices of BCRP start and/or end with glycine or proline (Figure 5C and Figure 3S), similar to that observed for P-gp. Residues that form the TMs are mostly hydrophobic, while the intracellular and extracellular loops contain more hydrophilic residues. The relative high amino acid identity in the TMDs and the pattern of residue distribution suggest a good quality of the sequence alignment. Li et al (Li et al., 2007) were unable to find adequate sequence identity between P-gp and BCRP. This is likely due to the major shifts in our experimentally determined topology. For example, the large intracellular loop connecting TM2 and TM3 in the computer-predicted topology does not exist in our experimental topology model. We found that, based on the experimental topology model, the amino acid identity between the TMDs of P-gp and BCRP was much improved.

The homology model using the MsbA structure as template (PDB code: 3B5W) (Ward et al., 2007) generated the substrate-unbound nucleotide-free apo inward-facing conformation of BCRP (Figure 6A). The structure of the NBD is well conserved among ABC transporters and has been extensively discussed (Li et al., 2007), and thus is not further discussed here. This dimeric model formed by 12 TM α-helices possesses a wide open inward-facing structure which is closed from the extracellular side. The entry of this open nucleotide-free structure is large enough to allow access of a bulky of BCRP substrates from either the inner leaflet or cytoplasm. Substrate-binding sites are likely located in the central cavity surrounded by TM α-helices. TM α-helices are connected by long intracellular or extracellular loops and extend far beyond the membrane interface with the only exception of TM3. The extracellular loop connecting TM1 and TM2 forms inter-monomer contacts with residues in the extracellular loop connecting TM5 and TM6, and thus may contribute to stabilization of the dimeric structure. In addition, inter-monomer interactions between the extracellular ends of the two centrally localized TM6 segments can be seen, similar to that observed for P-gp in cross-linking studies (Loo et al., 2003; Loo and Clarke, 1997). The unique feature of this BCRP model (Figure 6A) is the missing of the coupling helix 1 in the intracellular loop connecting TM 2 and TM3, which is present in all of the available template structures and could play a crucial role in the interactions between the NBD and the TMD of the same monomer. The first 18 residues at the NH2-terminus and residues 285 – 380 in the putative linker region connecting the NBD to the TMD of BCRP could not be modeled due to the lack of appropriate templates. This linker region of BCRP is much longer than those of other ABC efflux transporters and may serve as the coupling helix 1. Another common feature that was revealed in the X-ray structures of Sav1866, MsbA, and P-gp is that a second coupling helix (coupling helix 2) crosses over and associates with the NBD of the opposite monomer. This cross-over motif is also present in the homology model in the intracellular loop connecting TM4 and TM5 which may define the relative orientation of individual domains and allow flexibility in the transporter (Figure 6A). Glycine 553 in this region may be important for BCRP dimerization (Polgar et al., 2006). Similar wide open apo inward-facing conformations have been shown in structures of other ABC transporters (Chami et al., 2002; Hofacker et al., 2007; Ward et al., 2007).

Figure 6
Homology models of BCRP in the open (A) and closed (B) apo inward-facing nucleotide-free apo conformations

The second homology model of BCRP (Figure 6B) was developed based on the substrate-bound nucleotide-free structure of mouse P-gp (PDB code: 3G60) (Aller et al., 2009). This model represents the closed apo nucleotide-free inward-facing conformation of BCRP that likely occurs in the catalytic cycle after substrates enter the wide open apo inward-facing conformation. Comparing the open and closed nucleotide-free models, we found that TM4 and TM5 of BCRP rotate ~30° with a rotation center at the extracellular side of the TMD near the putative substrate-binding cavity. This rigid body motion is possibly transmitted to the NBDs by the coupling helix 2 and forces the NBDs to close the wide open entry from the intracellular side. The distance between the two NBDs in the closed apo nucleotide-free conformation, although becomes much shorter, still does not allow direct interactions of the NBDs with each other. The rotation also forces TMs 1 – 3 and 6 to similarly change their positions. These conformational changes result in an intracellular entry between the two TMDs in the closed apo structure which is ~20 Å narrower (a reduction from 90 Å to 70 Å) as compared with the open apo structure (Figure 6). Such a domain rearrangement would alter the shape of the substrate-binding cavity which is formed primarily by residues in the TMs by making it more compact, thus allowing interactions of substrates with both monomers at the same time. The results of homology modeling are consistent with our experimental data of electron crystallography. First, our EM data also demonstrated a similar rotation of the projection structure of BCRP in the presence of mitoxantrone (Figure 4). Second, such rotation also resulted in a closer packing of the BCRP molecules in the presence of mitoxantrone (Table I). Taken together, both the EM data and homology modeling suggest that the BCRP dimer could become more compact upon substrate binding.

We further examined if the homology models of BCRP can match with the densities in the corresponding projection maps. This was performed by aligning two BCRP dimers of the models related by a 2-fold screw axis, which correspond to the p121 plane group symmetry of the 2-D crystals, with the EM maps using the Chimera program. In the drug-bound map, the TM α-helices align well with the high-density regions (Figure 7A–D). In the drug-free map, the larger tilt angers of TM α-helices appear to cause densities with more elongated areas (Figure 7E–H). In both maps, two BCRP dimers cover the whole unit cell. It is worth noting that the dimerization pattern of the open apo model (Figure 7E–H) is similar to the oligomeric structure of the open apo form of MsbA resolved in its X-ray crystal structure (Ward et al., 2007) (PDB code 3B5W). Overall, the fitting again suggests that our EM data and homology modeling appear to be in good agreement. The fitting supports the crystallographic data that the asymmetric unit cell in both projection maps may accommodate two BCRP dimers. Individual secondary structure elements (e.g., 12 TM α-helices) may not be clearly defined in the 2-D projection maps. This is because the BCRP molecule is not reconstituted in lipid and we are uncertain whether the molecule is perpendicular to the crystal plane. Also, in cryo projection maps, TM α-helices, NBDs, and underlying loops will be superimposed in the structure (Kuo et al., 2005). Hence, only the overall densities and shape of the BCRP models could be rationalized in the projection maps by the fitting. For the same reasons, we did not try to improve the models by such fitting as this would require a 3-D map.

Figure 7
Alignment of the BCRP models with projection maps

In conclusion, in the present study, we have described the successful crystallization of the first well-diffracting 2-D crystals of BCRP at a resolution that provides significant structural information. For the first time, we demonstrated the conformational change of BCRP in the presence of its substrate drug, mitoxantrone. Homology modeling helped interpret the structural data. Our results are consistent with most of the biochemical data available for BCRP. These structural data enhance our understanding of the drug binding and transport mechanism of BCRP and establish a basis for further structure-function analyses of this important drug transporter. The exact number of TM α-helices, their relative orientations and assignment in the protein sequence cannot be resolved from the projection structures. This will require the calculation of a 3-D map, which is currently underway.

Experimental Procedures

Expression and purification of BCRP in Pichia pastoris

Expression of BCRP in Pichia pastoris was carried out as previously described (Mao et al., 2004; Wu et al., 2005). Further details for expression and purification of BCRP are described in the Supplemental Data.

Measurement of BCRP ATPase activity

ATPase activity of purified BCRP was measured as described (Mao et al., 2004). Further details can be found in the Supplemental Data.

Two-dimensional crystallization, electron microscopy and imaging processing

The 2-D crystals of BCRP were prepared essentially the same as previously described (Rosenberg et al., 2005). BCRP (~0.03 mg/ml) was incubated with a mixture containing 10% (w/v) poly-ethylene glycol 4000, 100 mM ammonium sulfate, 0.1% (w/v) DDM in Tris-HCl buffer (pH 7.4) with and without 5 mM mitoxantrone for 17 h at 4°C. The sample was incubated with 300 mesh gold or molybdenum grids coated with continuous carbon (TAAB Laboratories Equipment Ltd, Berkshire, UK). The crystallization experiments were evaluated by electron microscopy following negative staining in 2% (w/v) uranyl acetate. The use of heavy metal gold or molybdenum grids is unlikely to have changed the conformation of the protein because both were used for non-mitoxantrone bound and mitoxantrone bound, and thus if they were eliciting an effect, we would have seen this for the non-mitoxantrone bound experiments. We saw no additional conformational changes using a gold grid instead of a molybdenum grid and vice versa. Some specimens were frozen in liquid ethane and subsequently transferred to a cryoholder cooled by liquid N2 to a temperature of approximately −175°C. Images were collected on a Tecnai F20 field-emission microscope at the University of Leeds at 200 keV at liquid N2 temperatures, magnification of 50,000 ×, and mean underfocus ranging from 4,000 to 15,000 Å. Images were also collected on a FEI Tecnai G2 Polara microscope (300 keV) at the University of Manchester with a Gatan CCD camera and a CM200 at 200 keV equipped with a Tietz CCD camera at Imperial College, London. Images were recorded at 10 – 12 e/Å2. Images were recorded on Kodak SO-163 film and developed for 12 min in a full-strength Kodak D19 developer or recorded on CCD camera. We used the methods described in the Supplemental Data to do the image processing with MRC and 2dx software.

Determination of membrane topology of BCRP by epitope insertion and immunofluorescence

HA-tagged BCRP mutants with the HA (YPYDVPDYA) tags inserted, one at a time, at positions immediately following the residues 435, 445, 460, 470, 540, and 550 were generated by epitope insertion mutagenesis. The pcDNA3.1 constructs containing HA-tagged BCRP mutant cDNAs were confirmed by DNA sequencing and used for transient transfection into HEK293 cells. Expression of HA-tagged BCRP mutants was then analyzed by immunoblotting using the BCRP-specific antibody BXP-21 and the antibody against the HA tag. The efflux activity of HA-tagged BCRP mutants and the location of the HA tags with respect to the plasma membrane (intracellular or extracellular) were determined using a flow cytometric efflux assay and immunofluorescence confocal microscopy, respectively. When permeabilization of cells was needed, 0.01% (v/v) Triton X-100 was used. All the above methods were essentially the same as previously described (Wang et al., 2008).

Homology modeling of BCRP

Based on the topology structure we determined (Wang et al., 2008), we performed homology modeling to generate the open and closed apo nucleotide-free conformations of BCRP. Primary sequence of human BCRP was taken from the Universal Protein Resource (http://www.uniprot.org, accession code: Q9UNQ0). Crystal structures of templates were obtained from the Brookhaven Protein Data Bank (http://www.rcsb.org/). The closed substrate-bound inward-facing form of mouse P-gp (Aller et al., 2009) (PDB code: 3G60) and the open substrate-unbound inward-facing form of MsbA (Ward et al., 2007) (PDB code: 3B5W) (both are nucleotide-free) were used as full-length templates. MsbA was used as the template of the open substrate-unbound inward-facing conformation of BCRP because P-gp structure in such a conformation has not been resolved. The topology of the outward-facing nucleotide-bound form of Sav1866 (Dawson and Locher, 2006) (PDB code: 2HYD) was also used in the refinement of sequence alignment. TM boundaries of the templates used in sequence alignment were derived from X-ray structures of the respective transporters. Two homology models of BCRP were built with one representing the substrate-free open apo inward-facing conformation based on MsbA and the other representing the substrate-bound closed apo inward-facing conformation based on the mouse P-gp structure. Further details can be found in the Supplemental Data.

Supplementary Material

Acknowledgments

We thank Professor Karl Kadler, Dr. Alan Rosen, Dr. Roger Meadows, Mr Les Lockey (University of Manchester), Professor John Trinick and Dr. Peiyi Wang (University of Leeds), Professor Marin Van Heel, Dr. Tilliman Pape, and Dr Raffa Carzaniga (Imperial College, London) for access and assistance with the respective microscopes. We thank Dr. Vinzenz Unger (Yale University), Dr. Anchi Cheng (Scripps Research Institute, San Diego, California), and Dr. Linus Johannissen (University of Manchester) for calculation of the phase quality plot, assistance with image processing, and the help in writing code, respectively. We acknowledge Dr. Honggang Wang (University of Washington) for technical assistance with confocal microscope. This work was supported by the Leukemia Research Fund, London, (to MFR) a VIP Fellowship from the Wellcome Trust to MFR,, in part by Grant 081406/Z/06/Z from the Wellcome Trust, and by the NIH grant GM073715 (to QM).

References

  • Aller SG, Yu J, Ward A, Weng Y, Chittaboina S, Zhuo R, Harrell PM, Trinh YT, Zhang Q, Urbatsch IL, Chang G. Structure of P-glycoprotein reveals a molecular basis for poly-specific drug binding. Science. 2009;323(5922):1718–1722. [PMC free article] [PubMed]
  • Appel M, Hizlan D, Vinothkumar KR, Ziegler C, Kuhlbrandt W. Conformations of NhaA, the Na+/H+ exchanger from Escherichia coli, in the pH-activated and ion-translocating states. J Mol Biol. 2009;388(3):659–672. [PubMed]
  • Bailey S. The CCP4 suite: programs for protein crystallography. Acta Cryst. 1994;D50:760–763. [PubMed]
  • Chami M, Steinfels E, Orelle C, Jault JM, Di Pietro A, Rigaud JL, Marco S. Three-dimensional structure by cryo-electron microscopy of YvcC, an homodimeric ATP-binding cassette transporter from Bacillus subtilis. J Mol Biol. 2002;315(5):1075–1085. [PubMed]
  • Dawson RJ, Locher KP. Structure of a bacterial multidrug ABC transporter. Nature. 2006;443(7108):180–185. [PubMed]
  • Glavinas H, Kis E, Pal A, Kovacs R, Jani M, Vagi E, Molnar E, Bansaghi S, Kele Z, Janaky T, Bathori G, von Richter O, Koomen GJ, Krajcsi P. ABCG2 (breast cancer resistance protein/mitoxantrone resistance-associated protein) ATPase assay: a useful tool to detect drug-transporter interactions. Drug Metab Dispos. 2007;35(9):1533–1542. [PubMed]
  • Gonen T, Cheng Y, Sliz P, Hiroaki Y, Fujiyoshi Y, Harrison SC, Walz T. Lipid-protein interactions in double-layered two-dimensional AQP0 crystals. Nature. 2005;438(7068):633–638. [PMC free article] [PubMed]
  • Hazai E, Bikadi Z. Homology modeling of breast cancer resistance protein (ABCG2) J Struct Biol. 2008;162(1):63–74. [PubMed]
  • Henderson R, Baldwin JM, Downing KH, Lepault J, Zemlin F. Structure of purople membrane from Halobacterium halobium - recording, measurement and evaluation of electron-micrographs at 3.5 A resolution. Ultramicroscopy. 1986;19:147–178.
  • Hofacker M, Gompf S, Zutz A, Presenti C, Haase W, van der Does C, Model K, Tampe R. Structural and functional fingerprint of the mitochondrial ATP-binding cassette transporter Mdl1 from Saccharomyces cerevisiae. J Biol Chem. 2007;282(6):3951–3961. [PubMed]
  • Holm PJ, Bhakat P, Jegerschold C, Gyobu N, Mitsuoka K, Fujiyoshi Y, Morgenstern R, Hebert H. Structural basis for detoxification and oxidative stress protection in membranes. J Mol Biol. 2006;360(5):934–945. [PubMed]
  • Honjo Y, Hrycyna CA, Yan QW, Medina-Perez WY, Robey RW, van de Laar A, Litman T, Dean M, Bates SE. Acquired mutations in the MXR/BCRP/ABCP gene alter substrate specificity in MXR/BCRP/ABCP-overexpressing cells. Cancer Res. 2001;61(18):6635–6639. [PubMed]
  • Kuhlbrandt W, Wang DN, Fujiyoshi Y. Atomic model of plant light-harvesting complex by electron crystallography. Nature. 1994;367(6464):614–621. [PubMed]
  • Kuo A, Domene C, Johnson LN, Doyle DA, Venien-Bryan C. Two different conformational states of the KirBac3.1 potassium channel revealed by electron crystallography. Structure. 2005;13(10):1463–1472. [PubMed]
  • Larue K, Kimber MS, Ford R, Whitfield C. Biochemical and structural analysis of bacterial O-antigen chain length regulator proteins reveals a conserved quaternary structure. J Biol Chem. 2009;284(11):7395–7403. [PMC free article] [PubMed]
  • Li YF, Polgar O, Okada M, Esser L, Bates SE, Xia D. Towards understanding the mechanism of action of the multidrug resistance-linked half-ABC transporter ABCG2: a molecular modeling study. J Mol Graph Model. 2007;25(6):837–851. [PubMed]
  • Loo TW, Bartlett MC, Clarke DM. Simultaneous binding of two different drugs in the binding pocket of the human multidrug resistance P-glycoprotein. J Biol Chem. 2003;278(41):39706–39710. [PubMed]
  • Loo TW, Clarke DM. Drug-stimulated ATPase activity of human P-glycoprotein requires movement between transmembrane segments 6 and 12. J Biol Chem. 1997;272(34):20986–20989. [PubMed]
  • Loo TW, Clarke DM. Defining the drug-binding site in the human multidrug resistance P-glycoprotein using a methanethiosulfonate analog of verapamil, MTS-verapamil. J Biol Chem. 2001;276(18):14972–14979. [PubMed]
  • Maliepaard M, Scheffer GL, Faneyte IF, van Gastelen MA, Pijnenborg AC, Schinkel AH, van De Vijver MJ, Scheper RJ, Schellens JH. Subcellular localization and distribution of the breast cancer resistance protein transporter in normal human tissues. Cancer Res. 2001;61(8):3458–3464. [PubMed]
  • Mao Q, Conseil G, Gupta A, Cole SP, Unadkat JD. Functional expression of the human breast cancer resistance protein in Pichia pastoris. Biochem Biophys Res Commun. 2004;320(3):730–737. [PubMed]
  • Mao Q, Unadkat JD. Role of the breast cancer resistance protein (ABCG2) in drug transport. Aaps J. 2005;7(1):E118–133. [PMC free article] [PubMed]
  • McDevitt CA, Collins RF, Conway M, Modok S, Storm J, Kerr ID, Ford RC, Callaghan R. Purification and 3D structural analysis of oligomeric human multidrug transporter ABCG2. Structure. 2006;14(11):1623–1632. [PubMed]
  • Murata K, Mitsuoka K, Hirai T, Walz T, Agre P, Heymann JB, Engel A, Fujiyoshi Y. Structural determinants of water permeation through aquaporin-1. Nature. 2000;407(6804):599–605. [PubMed]
  • Ozvegy-Laczka C, Koblos G, Sarkadi B, Varadi A. Single amino acid (482) variants of the ABCG2 multidrug transporter: major differences in transport capacity and substrate recognition. Biochim Biophys Acta. 2005;1668(1):53–63. [PubMed]
  • Polgar O, Ozvegy-Laczka C, Robey RW, Morisaki K, Okada M, Tamaki A, Koblos G, Elkind NB, Ward Y, Dean M, Sarkadi B, Bates SE. Mutational studies of G553 in TM5 of ABCG2: a residue potentially involved in dimerization. Biochemistry. 2006;45(16):5251–5260. [PMC free article] [PubMed]
  • Polgar O, Robey RW, Bates SE. ABCG2: structure, function and role in drug response. Expert Opin Drug Metab Toxicol. 2008;4(1):1–15. [PubMed]
  • Pozza A, Perez-Victoria JM, Sardo A, Ahmed-Belkacem A, Di Pietro A. Purification of breast cancer resistance protein ABCG2 and role of arginine-482. Cell Mol Life Sci. 2006;63(16):1912–1922. [PubMed]
  • Robey RW, To KK, Polgar O, Dohse M, Fetsch P, Dean M, Bates SE. ABCG2: a perspective. Adv Drug Deliv Rev. 2009;61(1):3–13. [PMC free article] [PubMed]
  • Rosenberg MF, Callaghan R, Modok S, Higgins CF, Ford RC. Three-dimensional structure of P-glycoprotein: the transmembrane regions adopt an asymmetric configuration in the nucleotide-bound state. J Biol Chem. 2005;280(4):2857–2862. [PubMed]
  • Rosenberg MF, Kamis AB, Aleksandrov LA, Ford RC, Riordan JR. Purification and crystallization of the cystic fibrosis transmembrane conductance regulator (CFTR) J Biol Chem. 2004;279(37):39051–39057. [PubMed]
  • Rosenberg MF, Kamis AB, Callaghan R, Higgins CF, Ford RC. Three-dimensional structures of the mammalian multidrug resistance P-glycoprotein demonstrate major conformational changes in the transmembrane domains upon nucleotide binding. J Biol Chem. 2003;278(10):8294–8299. [PubMed]
  • Sarkadi B, Homolya L, Szakacs G, Varadi A. Human multidrug resistance ABCB and ABCG transporters: participation in a chemoimmunity defense system. Physiol Rev. 2006;86(4):1179–1236. [PubMed]
  • Slotboom DJ, Sobczak I, Konings WN, Lolkema JS. A conserved serine-rich stretch in the glutamate transporter family forms a substrate-sensitive reentrant loop. Proc Natl Acad Sci U S A. 1999;96(25):14282–14287. [PubMed]
  • Valpuesta JM, Carrascosa JL, Henderson R. Analysis of electron microscope images and electron diffraction patterns of thin crystals of phi 29 connectors in ice. J Mol Biol. 1994;240(4):281–287. [PubMed]
  • Wakabayashi S, Pang T, Su X, Shigekawa M. A novel topology model of the human Na(+)/H(+) exchanger isoform 1. J Biol Chem. 2000;275(11):7942–7949. [PubMed]
  • Wang H, Lee EW, Cai X, Ni Z, Zhou L, Mao Q. Membrane topology of the human breast cancer resistance protein (BCRP/ABCG2) determined by epitope insertion and immunofluorescence. Biochemistry. 2008;47(52):13778–13787. [PMC free article] [PubMed]
  • Ward A, Reyes CL, Yu J, Roth CB, Chang G. Flexibility in the ABC transporter MsbA: Alternating access with a twist. Proc Natl Acad Sci U S A. 2007;104(48):19005–19010. [PubMed]
  • Wu P, Oleschuk CJ, Mao Q, Keller BO, Deeley RG, Cole SP. Analysis of human multidrug resistance protein 1 (ABCC1) by matrix-assisted laser desorption ionization/time of flight mass spectrometry: toward identification of leukotriene C4 binding sites. Mol Pharmacol. 2005;68(5):1455–1465. [PubMed]
  • Xu J, Liu Y, Yang Y, Bates S, Zhang JT. Characterization of oligomeric human half-ABC transporter ATP-binding cassette G2. J Biol Chem. 2004;279(19):19781–19789. [PubMed]